Search filters
Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)

Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)

11/03/2022

The health insurer does not yet fully reimburse Jardiance (Empagliflozin)® 10 mg for the treatment of HFpEF (Ejection fraction...

Extension to TerugBetaalRegeling Acecort®

Extension to TerugBetaalRegeling Acecort®

09/03/2022

Recently also Acecort® 2 and 3 mg tablets have been registered. The health insurer will not reimburse the cost in full. The...

Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI)  5 mg

Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg

17/02/2022

The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine...

Termination TerugBetaalRegeling Tecfidera®

Termination TerugBetaalRegeling Tecfidera®

08/12/2021

As of December 1, 2021, a Personal Contribution for Tecfidera is no longer required. Health insurers will once again fully...

Termination TerugBetaalRegeling Fragmin®2500

Termination TerugBetaalRegeling Fragmin®2500

01/12/2021

From January 1st 2022 onwards, the reimbursement scheme for FRAGMIN (dalteparine)2500 INJVLST 12.500IE/ML WWSP 0,2ML will be...

You are currently offline. Some pages or content may fail to load.